129 related articles for article (PubMed ID: 618581)
21. Cellular cytotoxicity and serum inhibition in normal mice following transfer of xenogeneic tumor-sensitized cells.
Fisher B; Wolmark N; Saffer EA
Cancer Res; 1979 Dec; 39(12):4772-6. PubMed ID: 498106
[No Abstract] [Full Text] [Related]
22. [Effect of silica on the anti-tumour activity of "Corynebacterium parvum" (author's transl)].
Mazurek C; Stiffel C; Chalvet H; Biozzi G
Ann Immunol (Paris); 1979; 130(6):815-26. PubMed ID: 232975
[TBL] [Abstract][Full Text] [Related]
23. In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes.
Seto M; Takahashi T; Nakamura S; Matsudaira Y; Nishizuka Y
Cancer Res; 1983 Oct; 43(10):4768-73. PubMed ID: 6192909
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
Kreider JW; Bartlett GL; Purnell DM; Webb S
Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
[TBL] [Abstract][Full Text] [Related]
25. Further observations on the inhibition of tumor growth by corynebacterium parvum with cyclophosphamide.
Fisher B; Rubin H; Wolmark N
J Natl Cancer Inst; 1976 Aug; 57(2):317-22. PubMed ID: 1003514
[TBL] [Abstract][Full Text] [Related]
26. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. II. Effect of cortisone acetate.
Fisher B; Rubin H; Saffer E; Wolmark N
J Natl Cancer Inst; 1976 Mar; 56(3):571-4. PubMed ID: 1255788
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of murine tumor with syngeneic antitumor serum plus BCG.
Yamazaki M; Saito M; Abe S; Mizuno D
Jpn J Exp Med; 1983 Feb; 53(1):27-32. PubMed ID: 6876475
[TBL] [Abstract][Full Text] [Related]
28. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
29. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
Wolmark N; Fisher B
Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
[No Abstract] [Full Text] [Related]
30. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
31. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. V. Comparison of the effects of tilorone hydrochloride, levamisole, methanol-soluble fraction of Mycobacterium butyricum, BCG, and a nonviable aqueous ether extract of Brucella abortus preparation in treatment of mice with tumors.
Fisher B; Linta J; Hanlon J; Saffer E
J Natl Cancer Inst; 1978 Feb; 60(2):391-9. PubMed ID: 413929
[No Abstract] [Full Text] [Related]
32. Effect of prolonged Corynebacterium parvum and cyclophosphamide administration on spontaneously occurring metastases.
Wolmark N; Fisher B
Surg Forum; 1975; 26():136-8. PubMed ID: 1216089
[No Abstract] [Full Text] [Related]
33. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
[TBL] [Abstract][Full Text] [Related]
34. Response of tumors to biologic modifiers and chemotherapeutic agents.
Katsuoka Y; deKernion JB
Tokai J Exp Clin Med; 1983 May; 8(2):175-85. PubMed ID: 6658848
[TBL] [Abstract][Full Text] [Related]
35. [Antitumor effect of Corynebacterium parvum on C3H mouse bearing MH-134 tumor].
Nakamura K; Miwa H; Hashimoto O; Inoue T; Orita K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1046-51. PubMed ID: 7184438
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
[TBL] [Abstract][Full Text] [Related]
37. Chemoimmunotherapy of murine mammary adenocarcinomas.
Ames IH
Anticancer Res; 2004; 24(4):2249-56. PubMed ID: 15330169
[TBL] [Abstract][Full Text] [Related]
38. Role of T-cell subsets in the destruction of established metastases of 13762A rat mammary adenocarcinoma.
Howell LE; Kreider JW; Bartlett GL
J Natl Cancer Inst; 1986 Jul; 77(1):187-93. PubMed ID: 3487670
[TBL] [Abstract][Full Text] [Related]
39. A bladder tumor model response to immunotherapy.
deKernion JB; Ramming KP; Fraser K
Natl Cancer Inst Monogr; 1978 Dec; (49):333. PubMed ID: 748789
[TBL] [Abstract][Full Text] [Related]
40. Cell-mediated immunity and serum blocking factors in cancer patients during chemotherapy and immunotherapy.
Noonan FP; Halliday WJ; Wall DR; Clunie GJ
Cancer Res; 1977 Aug; 37(8 Pt 1):2473-80. PubMed ID: 872076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
